Alexander Kabiri
Optometrist · Queens Village, NYNPI 1184725152
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (57.4%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 21 manufacturers reported payments, led by Bausch & Lomb Americas Inc. at 26.9% of the total. Reporting peaked in 2019 at $107,008 and has fallen 61.7% since, to $40,935 in 2025. Among optometrist clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 538 payments — averaging $499.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb Americas Inc.$72K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$56K
- Shire North American Group Inc$31K
- Aerie Pharmaceuticals, Inc.$30K
- Eyevance Pharmaceuticals LLC$28K
- Sun Pharmaceutical Industries Inc.$21K
- plus $29K from 15 others
Across 1 payment — averaging $3200.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bausch Health US, LLC$3K
What the payments were for
- Consulting fees$75,59028%
- Speaking & faculty fees$154,13757%
- Travel & lodging$24,6059%
- Food & beverage$13,9335%
- Education$2010%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb Americas Inc. | 98 | $72,346 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 118 | $55,911 |
| Shire North American Group Inc | 47 | $31,463 |
| Aerie Pharmaceuticals, Inc. | 45 | $30,416 |
| Eyevance Pharmaceuticals LLC | 44 | $28,348 |
| Sun Pharmaceutical Industries Inc. | 39 | $21,075 |
| Kala Pharmaceuticals, Inc. | 17 | $10,029 |
| Novartis | 51 | $7,771 |
| AbbVie(2 entities) | 24 | $6,893 |
| Vertical Pharmaceuticals, LLC | 1 | $2,148 |
| Alcon | 11 | $405 |
| Harrow Eye, LLC | 17 | $356 |
| Dompe US, Inc. | 8 | $346 |
| Mallinckrodt Hospital Products Inc. | 5 | $241 |
| Quidel Corporation | 3 | $196 |
| Biotissue Holdings Inc. | 1 | $148 |
| Oyster Point Pharma, Inc. | 3 | $135 |
| Sight Sciences, Inc. | 1 | $126 |
| Tarsus Pharmaceuticals, Inc. | 3 | $80 |
| Coopervision Inc. | 1 | $19 |
| Amgen | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$268,466 in reported general payments places this provider in the 95th percentile of 2,743 optometrist providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MieboPerfluorohexyloctane/Pf | 617 | $454,030 |
| XiidraLifitegrast | 641 | $425,720 |
| VyzultaLatanoprostene Bunod | 444 | $110,020 |
| VevyeCyclosporine | 74 | $57,693 |
| RestasisCyclosporine | 70 | $43,359 |
| Azelastine Hcl | 2,778 | $22,708 |
| CombiganBrimonidine Tartrate/Timolol | 97 | $20,858 |
| LumiganBimatoprost | 52 | $15,374 |
| RhopressaNetarsudil Mesylate | 47 | $14,986 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 76 | $14,788 |
| EysuvisLoteprednol Etabonate | 22 | $10,458 |
| AlrexLoteprednol Etabonate | 23 | $6,681 |
| RocklatanNetarsudil Mesylat/Latanoprost | 20 | $6,493 |
| Loteprednol Etabonate | 23 | $3,522 |
| Brimonidine Tartrate | 115 | $2,426 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Miebo, Xiidra, Vyzulta | $72,346 | $989,7701,702 claims |
| AbbVieRestasis, Combigan, Lumigan | $6,893 | $79,590219 claims |
| Harrow Eye, LLCVevye | $356 | $57,69374 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $30,416 | $21,47967 claims |
| AlconSimbrinza | $405 | $14,78876 claims |
| Kala Pharmaceuticals, Inc.Eysuvis | $10,029 | $10,45822 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCAlrex, Loteprednol Etabonate | $55,911 | $10,20346 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,743 optometrist providers in New York.
Other optometrist in Queens Village
- Roy KlineLake Katrine$822K
- Susan ResnickNew York$463K
- Murray FingeretHewlett$374K
- Albert MorierSlingerlands$347K
- Denise WhittamNew York$343K
- Justin BazanBrooklyn$303K
- Jennifer TsaiNew York$275K
- Sophia VisanjiNew York$233K
- Jason ComptonNew York$181K
- Dana SalgadoAlbany$119K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.